v3.26.1
Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)
6 Months Ended
Jun. 30, 2026
Deferred Royalty Obligation [Abstract]  
Schedule of Royalty Obligation transaction

The following table shows the activity of the deferred royalty obligation for the six months ended June 30, 2026:

 

 

 

June 30,

 

 

 

2026

 

 

 

(in thousands)

 

Liability related to sale of future Vaxcyte royalties - beginning balance

 

$

219,536

 

Non-cash interest expense associated with the sale of future Vaxcyte royalties

 

 

19,329

 

Amortization of issuance costs

 

 

199

 

Liability related to the sale of future Vaxcyte royalties - ending balance

 

$

239,064